Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
Lifts full-year outlook as obesity drug boom accelerates
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
Rahul Bhatnagar succeeds Aditya Narayan, who completed a decade-long distinguished tenure
The company posted revenue of €1,267 million, up 6% on a constant currency basis
The transaction marks a clear portfolio reshuffle for Indoco
His appointment is expected to further strengthen the company’s financial governance and regional operational strategy across South Asia
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
Tamir brings more than 20 years of experience in the medical technology sector
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
Subscribe To Our Newsletter & Stay Updated
